IMGT®, the international ImMunoGeneTics information system®

logo IMGT

Composite proteins for clinical applications (CPCA)

The Composite proteins for clinical applications (CPCA) identify genetically engineered proteins proteins that include fusion proteins other than FPIA and result from the fusion of peptide, region and/or domain of protein(s) of different sources, synthetic proteins, and engineered peptide, region and/or domain of protein(s) of different sources linked covalently by disulfide bridges or by short chemical linkers. The Fc may be present and used as a transporter or to increase the product half-life but, not for its effector properties that are rather avoided. CPCA do not have a special suffix (stem) in INN but are designated by a name related to their mode of action (MOA) or biological property.

FPIA (Fusion proteins for immune applications) and CPCA (Composite proteins for clinical applications) correspond to in vitro engineered proteins of the WHO/INN programme. These categories FPIA and CPCA will be proposed for the INN definition in publication lists.